IL156046A0 - Condensed purine derivatives as a1 adenosine receptor antagonists - Google Patents

Condensed purine derivatives as a1 adenosine receptor antagonists

Info

Publication number: IL156046A0
Authority: IL; Israel
Prior art keywords: receptor antagonists; adenosine receptor; purine derivatives; condensed purine; condensed
Prior art date: 2000-12-01

Application number

IL15604601A

Other languages

English (en)

Original Assignee

Biogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-01

Filing date

2001-11-30

Publication date

2003-12-23

2001-11-30 Application filed by Biogen Inc filed Critical Biogen Inc

2003-12-23 Publication of IL156046A0 publication Critical patent/IL156046A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL15604601A 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists IL156046A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25065800P	2000-12-01	2000-12-01
PCT/US2001/044991 WO2002044182A1 (en)	2000-12-01	2001-11-30	Condensed purine derivatives as a1 adenosine receptor antagonists

Publications (1)

Publication Number	Publication Date
IL156046A0 true IL156046A0 (en)	2003-12-23

Family

ID=22948640

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15604601A IL156046A0 (en)	2000-12-01	2001-11-30	Condensed purine derivatives as a1 adenosine receptor antagonists

Country Status (32)

Country	Link
US (2)	US6605601B2 (zh)
EP (1)	EP1347981B1 (zh)
JP (2)	JP2004514723A (zh)
KR (1)	KR20040011439A (zh)
CN (1)	CN100497340C (zh)
AR (1)	AR035400A1 (zh)
AT (1)	ATE394402T1 (zh)
AU (2)	AU2002219977B2 (zh)
BG (1)	BG107849A (zh)
BR (1)	BR0115833A (zh)
CA (1)	CA2430508C (zh)
CZ (1)	CZ20031513A3 (zh)
DE (1)	DE60133931D1 (zh)
EA (1)	EA009814B1 (zh)
EE (1)	EE200300260A (zh)
ES (1)	ES2305139T3 (zh)
GE (1)	GEP20094697B (zh)
HU (1)	HUP0400530A3 (zh)
IL (1)	IL156046A0 (zh)
IS (1)	IS6821A (zh)
MX (1)	MXPA03004857A (zh)
MY (1)	MY127120A (zh)
NO (1)	NO20032483L (zh)
NZ (1)	NZ526511A (zh)
PL (1)	PL362642A1 (zh)
SK (1)	SK6552003A3 (zh)
TR (1)	TR200300766T2 (zh)
TW (1)	TWI293301B (zh)
UA (1)	UA75625C2 (zh)
WO (1)	WO2002044182A1 (zh)
YU (1)	YU42903A (zh)
ZA (2)	ZA200304067B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1251130B1 (en) *	1999-12-24	2005-02-16	Kyowa Hakko Kogyo Co., Ltd.	Fused purine derivatives
ES2305139T3 (es) *	2000-12-01	2008-11-01	Biogen Idec Ma Inc.	Derivados de purina condensados como antagonistas de receptores de adenosina a1.
WO2004074247A2 (en) *	2003-02-19	2004-09-02	Endacea, Inc.	A1 adenosine receptor antagonists
US20040229901A1 (en) *	2003-02-24	2004-11-18	Lauren Otsuki	Method of treatment of disease using an adenosine A1 receptor antagonist
WO2004096228A1 (en)	2003-04-25	2004-11-11	Novacardia, Inc.	Method of improved diuresis in individuals with impaired renal function
EP1637532A1 (en) *	2003-04-25	2006-03-22	Kyowa Hakko Kogyo Co., Ltd.	Fused pyrimidine derivative
JP4859666B2 (ja) *	2003-06-06	2012-01-25	エンダセア，インコーポレイテッド	Ａ１アデノシンレセプターアンタゴニスト
JP2008534445A (ja) *	2005-03-11	2008-08-28	アデリスファーマシューティカルズ，インコーポレイテッド	置換９−アルキルアデニンおよびその使用
US7795427B2 (en) *	2006-02-14	2010-09-14	New York University	Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
EP2001479A2 (en) *	2006-04-06	2008-12-17	Novacardia, Inc.	Co-administration of adenosine a1 receptor antagonists and anticonvulsants
DK2018380T3 (da)	2006-05-19	2012-01-23	Abbott Lab	CNS-aktiverede kondenserede bi-heterocyklisk-substituerede azabicykliske alkanderivater
CN101466383A (zh) *	2006-06-16	2009-06-24	美国诺华卡迪亚公司	包含低频率投与aa1ra的肾功能延长改善
DE602007010312D1 (de)	2006-06-23	2010-12-16	Incyte Corp	Purinonderivate als hm74a-agonisten
BRPI0713619A2 (pt)	2006-06-23	2013-01-15	Incyte Corp	composto ou prà-droga ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço, e, uso do composto.
US20090197900A1 (en) *	2007-03-29	2009-08-06	Howard Dittrich	Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20080242684A1 (en) *	2007-03-29	2008-10-02	Howard Dittrich	Methods of administration of adenosine a1 receptor antagonists
WO2011063268A2 (en) *	2009-11-19	2011-05-26	Biogen Idec Ma Inc	Novel synthetic methods
US20130109645A1 (en)	2010-03-31	2013-05-02	The united States of America,as represented by Secretary,Dept.,of Health and Human Services	Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
EP3735413B1 (en)	2018-01-04	2022-07-06	Impetis Biosciences Ltd.	Tricyclic compounds, compositions and medicinal applications thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06102662B2 (ja) *	1989-09-01	1994-12-14	協和醗酵工業株式会社	キサンチン誘導体
EP0423805B1 (en) *	1989-10-20	2000-08-23	Kyowa Hakko Kogyo Kabushiki Kaisha	Condensed purine derivatives
CA2254273C (en)	1991-09-23	2003-03-25	Florida State University	Preparation of substituted isoserine esters using metal alkoxides and .beta.-lactams
AU4471297A (en) *	1996-10-07	1998-05-05	Kyowa Hakko Kogyo Co. Ltd.	Fused purine derivatives
WO1998057651A1 (en) *	1997-06-18	1998-12-23	Discovery Therapeutics, Inc.	Compositions and methods for preventing restenosis following revascularization procedures
AU4396899A (en) *	1998-07-02	2000-01-24	Kyowa Hakko Kogyo Co. Ltd.	Remedies for diabetes
EP1251130B1 (en) *	1999-12-24	2005-02-16	Kyowa Hakko Kogyo Co., Ltd.	Fused purine derivatives
ES2305139T3 (es) *	2000-12-01	2008-11-01	Biogen Idec Ma Inc.	Derivados de purina condensados como antagonistas de receptores de adenosina a1.

2001
- 2001-11-30 ES ES01998550T patent/ES2305139T3/es not_active Expired - Lifetime
- 2001-11-30 BR BR0115833-3A patent/BR0115833A/pt not_active Application Discontinuation
- 2001-11-30 YU YU42903A patent/YU42903A/sh unknown
- 2001-11-30 SK SK655-2003A patent/SK6552003A3/sk not_active Application Discontinuation
- 2001-11-30 NZ NZ526511A patent/NZ526511A/en unknown
- 2001-11-30 WO PCT/US2001/044991 patent/WO2002044182A1/en not_active Ceased
- 2001-11-30 EP EP01998550A patent/EP1347981B1/en not_active Expired - Lifetime
- 2001-11-30 EA EA200300629A patent/EA009814B1/ru not_active IP Right Cessation
- 2001-11-30 UA UA2003066041A patent/UA75625C2/uk unknown
- 2001-11-30 AR ARP010105594A patent/AR035400A1/es unknown
- 2001-11-30 JP JP2002546552A patent/JP2004514723A/ja active Pending
- 2001-11-30 TR TR2003/00766T patent/TR200300766T2/xx unknown
- 2001-11-30 IL IL15604601A patent/IL156046A0/xx unknown
- 2001-11-30 PL PL01362642A patent/PL362642A1/xx not_active Application Discontinuation
- 2001-11-30 AU AU2002219977A patent/AU2002219977B2/en not_active Ceased
- 2001-11-30 GE GEAP20017016A patent/GEP20094697B/en unknown
- 2001-11-30 MY MYPI20015481A patent/MY127120A/en unknown
- 2001-11-30 AT AT01998550T patent/ATE394402T1/de not_active IP Right Cessation
- 2001-11-30 CN CNB018208711A patent/CN100497340C/zh not_active Expired - Fee Related
- 2001-11-30 KR KR10-2003-7007322A patent/KR20040011439A/ko not_active Abandoned
- 2001-11-30 EE EEP200300260A patent/EE200300260A/xx unknown
- 2001-11-30 CA CA2430508A patent/CA2430508C/en not_active Expired - Fee Related
- 2001-11-30 MX MXPA03004857A patent/MXPA03004857A/es active IP Right Grant
- 2001-11-30 DE DE60133931T patent/DE60133931D1/de not_active Expired - Lifetime
- 2001-11-30 HU HU0400530A patent/HUP0400530A3/hu unknown
- 2001-11-30 CZ CZ20031513A patent/CZ20031513A3/cs unknown
- 2001-11-30 US US09/997,740 patent/US6605601B2/en not_active Expired - Fee Related
- 2001-11-30 AU AU1997702A patent/AU1997702A/xx active Pending
- 2001-11-30 TW TW090129678A patent/TWI293301B/zh active
2003
- 2003-05-20 IS IS6821A patent/IS6821A/is unknown
- 2003-05-26 ZA ZA200304067A patent/ZA200304067B/en unknown
- 2003-05-27 BG BG107849A patent/BG107849A/bg unknown
- 2003-05-27 US US10/446,573 patent/US7022686B2/en not_active Expired - Fee Related
- 2003-06-02 NO NO20032483A patent/NO20032483L/no not_active Application Discontinuation
2004
- 2004-10-28 ZA ZA200408755A patent/ZA200408755B/xx unknown
2009
- 2009-12-07 JP JP2009278047A patent/JP2010053148A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2010053148A (ja)	2010-03-11
CA2430508C (en)	2010-05-18
EA009814B1 (ru)	2008-04-28
IS6821A (is)	2003-05-20
YU42903A (sh)	2006-05-25
PL362642A1 (en)	2004-11-02
ATE394402T1 (de)	2008-05-15
EA200300629A1 (ru)	2003-12-25
ZA200304067B (en)	2005-05-30
US6605601B2 (en)	2003-08-12
BR0115833A (pt)	2003-10-28
UA75625C2 (en)	2006-05-15
BG107849A (bg)	2004-01-30
US7022686B2 (en)	2006-04-04
EE200300260A (et)	2003-08-15
MXPA03004857A (es)	2003-08-19
AR035400A1 (es)	2004-05-26
TR200300766T2 (tr)	2004-09-21
NZ526511A (en)	2005-04-29
WO2002044182A1 (en)	2002-06-06
HUP0400530A2 (hu)	2004-06-28
EP1347981B1 (en)	2008-05-07
AU2002219977B2 (en)	2008-01-24
HK1059927A1 (zh)	2004-07-23
US20020111333A1 (en)	2002-08-15
US20030220358A1 (en)	2003-11-27
NO20032483D0 (no)	2003-06-02
HUP0400530A3 (en)	2007-05-29
AU1997702A (en)	2002-06-11
MY127120A (en)	2006-11-30
CZ20031513A3 (cs)	2003-09-17
EP1347981A1 (en)	2003-10-01
GEP20094697B (en)	2009-06-10
NO20032483L (no)	2003-07-30
JP2004514723A (ja)	2004-05-20
SK6552003A3 (en)	2003-12-02
CA2430508A1 (en)	2002-06-06
CN100497340C (zh)	2009-06-10
CN1481387A (zh)	2004-03-10
KR20040011439A (ko)	2004-02-05
ZA200408755B (en)	2005-07-27
TWI293301B (en)	2008-02-11
ES2305139T3 (es)	2008-11-01
DE60133931D1 (de)	2008-06-19

Publication	Publication Date	Title
AU6808901A (en)	2001-12-11	Adenosine a2a receptor antagonists
HUP0400530A3 (en)	2007-05-29	Condensed purine derivatives as a1 adenosine receptor antagonists
HUP0401925A3 (en)	2007-05-29	A2b adenosine receptor antagonists
IL161572A0 (en)	2004-09-27	Adenosine a2a receptor antagonists
IL155962A0 (en)	2003-12-23	Compounds specific to adenosine a1, a2a, and a3 receptors and uses thereof
IL158214A0 (en)	2004-05-12	8-heteroaryl xanthine adenosine a2b receptor antagonists
IL178396A0 (en)	2007-02-11	Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
AU1211802A (en)	2002-03-04	4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
IL161573A0 (en)	2004-09-27	[1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
PL373953A1 (en)	2005-09-19	7-amino-benzothiazole derivatives as adenosine receptor ligands
NO20020931D0 (no)	2002-02-26	Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger
HRP20030031A2 (en)	2004-02-29	4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
HUP0303533A3 (en)	2005-02-28	Adenosine a1 agonist adenosine derivatives
IL162444A (en)	2010-04-29	Triazolo-quinolin derivatives useful as adenosine receptor ligands
PL370565A1 (en)	2005-05-30	5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
AU3167402A (en)	2002-06-24	Aminotriazolopyridiine derivatives as adenosine receptor ligands
NO20015662L (no)	2002-01-23	Oralt aktive A1-adenosinreseptorantagonister
EP1636230A4 (en)	2010-06-16	ADENOSINE A1 RECEPTOR ANTAGONISTS
SI1401837T1 (sl)	2006-02-28	Purinski derivati kot antagonisti adenozinskega receptorja A2B
AU2002320199A1 (en)	2003-03-03	Purine derivatives as a2b adenosine receptor antagonists
SI1444233T1 (sl)	2011-11-30	Antagonisti adenozinskega receptorja A2B
HUP0203369A3 (en)	2004-12-28	Polycycloalkylpurines as adenosine receptor antagonists, process for their preparation and their use
HK1056359A (zh)	2004-02-13	作为嘌呤能受体拮抗剂的嘌呤衍生物
SI1246623T1 (sl)	2007-04-30	Spojine, specificne za adenozin A1, A2a in A3 receptor, in njihove uporabe
PL378983A1 (pl)	2006-06-26	Pochodne ksantyny jako antagoniści receptora adenozyny A2B